MDS Virtual Congress 2021 » Parkinson’s Disease: Clinical Trials

A Milestone-based approach to monitoring disease progression in Parkinson’s disease

M. Brumm, A. Siderowf, T. Simuni, C. Caspell-Garcia, L. Chahine, T. Foroud, V. Arnedo, A. Reimer, C. Tanner, K. Poston, D. Weintraub, S. Hutten, K. Kieburtz, K. Marek, C. Coffey (Iowa City, USA)

A new fully implantable Adaptive Deep Brain Stimulation system tested for the first time in patients with Parkinson’s Disease

T. Mandat, R. Eleopra, M. Lanotte, L. Lopiano, M. Yanssen, Y. Temel, E. Pirola, P. Rampini (Warsaw, Poland)

A Phase 2 Randomized Controlled Trial Repurposing Ambroxol as a Disease Modifying Treatment for Parkinson’s Disease Dementia.

SH. Pasternak, C. Silviera, K. Coleman, E. Finger, J. Wells, M. Borrie, S. Morrow, G. Zou, R. Bartha, P. Macdonald, ME. Jenkins, M. Jog, R. Tirona, CA. Rupar (London, Canada)

Adopting a low-cost multidisciplinary telemedicine approach for falls prevention in Parkinson´s Disease.

A. García-Bustillo, JM. Ramírez-Sanz, JL. Garrido-Labrador, A. Arnaiz-González, F. Valiñas-Sieiro, M. Allende-Río, JJ. González-Bernal, J. González-Santos, JF. Díez-Pastor, M. Jahouh, JM. Trejo-Gabriel-Galán, E. Cubo (Burgos, Spain)

Amantadine DR/ER Efficacy as Early Add-On for Motor Complications in Parkinson’s Disease

C. Tanner, J. Lytle, A. Formella (San Francisco, USA)

Amantadine DR/ER-Related Reduction in OFF and Dyskinesia Improved Patient-Rated Interference with Activities and Social Interactions

K. Lyons, R. Pahwa, N. Crouse, L. Llorens, R. Howard, A. Formella (Kansas City, USA)

Apathy Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial

T. Stiep, A. Ramirez-Zamora, A. Tröster, R. Jain, L. Chen, M. Okun (Gainesville, USA)

Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Analysis of Baseline Factors

A. Nicholas, C. Singer, I. Zhang, E. Pappert, B. Navia (Birmingham, USA)

Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Characterization of Acute Nausea During Dose Titration

W. Ondo, R. Hauser, A. Bowling, S. Isaacson, E. Pappert, B. Navia (Houston, USA)

Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact of Concomitant Antiemetics on Nausea and Vomiting

R. Hauser, S. Factor, W. Ondo, I. Zhang, E. Pappert, B. Navia (Tampa, USA)

Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Dyskinesia

K. Klos, J. Hui, I. Zhang, E. Pappert, B. Navia (Tulsa, USA)

Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Impulse Control Disorders

A. Espay, K. Markopoulou, I. Zhang, E. Pappert, B. Navia (Cincinnati, USA)

Are Mobile Persons with Parkinson Disease Necessarily More Active?

J. Zajac, J. Cavanaugh, T. Baker, C. Colón-Semenza, T. Deangelis, R. Duncan, D. Fulford, M. Lavalley, T. Nordahl, K. Rawson, M. Saint-Hilaire, C. Thomas, G. Earhart, T. Ellis (Boston, USA)

Azathioprine immunosuppression and disease modification in Parkinson’s disease (AZA-PD): a randomised double-blind placebo-controlled phase II clinical trial

J. Greenland, E. Cutting, S. Kadyan, S. Bond, A. Chhabra, C. Williams-Gray (Cambridge, United Kingdom)

Blindness analyses in STEADY-PD3: a phase III placebo-controlled double-blind randomized trial of Isradipine as a disease modifying agent in early Parkinson Disease

T. Mestre, S. Eberly, C. Grimes, D. Oakes, T. Simuni (Ottawa, Canada)

Celiac disease-related antibodies in Parkinson’s Disease patients: a case control study.

GUL. şahbaz, BOB. Barut, SDT. Tekol (Istanbul, Turkey)

Central pain in Parkinson’s disease

M. Elfekih, I. Bedoui, B. Douma, M. Mansour, H. Derbali, A. Riahi, M. Messelmani, J. Zaouali, R. Mrissa (Nabeul, Tunisia)

Cinpanemab in Early Parkinson’s Disease: Phase 2 SPARK Study Results

A. Lang, A. Siderowf, E. Macklin, W. Poewe, D. Brooks, H. Fernandez, O. Rascol, N. Giladi, F. Stocchi, C. Tanner, R. Postuma, D. Simon, E. Tolosa, B. Mollenhauer, M. Byrne, K. Fraser, J. Xiao, I. Sapir, J. Inra, R. Hutchison, M. Yang, T. Fox (Toronto, Canada)

Cinpanemab in Parkinson’s Disease: Imaging and Fluid Biomarker Results from the Phase 2 SPARK Study

RM. Hutchison, K. Fraser, M. Yang, B. Hirschhorn, J. Xiao, D. Scott, B. Bedell, K. Evans, D. Graham, L. Martarello, J. Beaver, J. Cedarbaum, T. Fox, A. Siderowf, A. Lang (Cambridge, USA)

Climb up! Head up! Effectiveness and feasibility of sport climbing in Parkinson’s disease

A. Langer, H. Zach, S. Hasenauer, A. Flotz, L. Gassner, R. Pokan, P. Dabnichki, L. Wizany, D. Roth, S. Zimmel, M. Treven, M. Schmoeger, U. Willinger, W. Maetzler (Wien, Austria)

Cuneiform Nucleus Deep Brain Stimulation for Freezing of Gait in Parkinson’s disease. Initial clinical report.

C. Luca, S. Chang, I. Cajigas, J. Guest, I. Haq, B. Noga, J. Jagid (Miami, USA)

CVT-301 (levodopa inhalation powder) improves Patient Global Impression of Change (PGIC) over 1 year in patients with Parkinson’s disease (PD): a meta-analysis

M. Saint-Hilaire, A. Corbin, P. Zhao, D. Kegler-Ebo (Boston, USA)

CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson’s disease (PD)

P. Lewitt, P. Zhao, A. Corbin, D. Kegler-Ebo, B. Blank (West Bloomfield, USA)

Decreased expression of trace amines receptors on lymphocytes in Parkinson’s disease

Z. Muruzheva, I. Ivleva, V. Maystrenko, O. Tumashova, M. Karpenko (Saint-Petersburg, Russian Federation)

Defining LRRK2-PD subsets based on olfactory function in the PPMI

K. Marek, A. Siderowf, C. Tanner, T. Simuni, L. Chahine, M. Brumm, C. Coffey (New Haven, USA)

Disease stage and nigrostriatal integrity predict motor progression in individuals with early Parkinson’s disease

H. Jackson, J. Anzures-Cabrera, K. Taylor, G. Pagano (Welwyn Garden City, United Kingdom)

Dual-task interference on weight-shifting in Parkinson’s Disease with freezing of gait and without freezing of gait

YT. Hung, CY. Tsai, RM. Wu, CY. Huang (Taipei, Taiwan)

Effect of physical exercises on gait speed in patients with Parkinson’s disease

D. Bueno, L. Oliveira, L. Ota, P. Polidoro, G. da Costa (Dracena, Brazil)

Effect of probiotics on MDS UPDRS in Parkinson disease at 12 weeks: A Randomized double-blind placebo-controlled trial

G. George, T. Iype (Thiruvananthapuram, India)

Effect of Venglustat by GBA Mutation Severity in Patients With Parkinson’s Disease

J. Peterschmitt, N. Giladi, R. Alcalay, G. Cutter, G. Höglinger, A. Schapira, C. Scherzer, T. Simuni, T. Gurevich, T. Gasser, C. Pacchetti, K. Marek, P. Minini, S. Sardi (Cambridge, USA)

Effects of Opicapone on Sleep in Patients with Parkinson’s Disease and Motor Fluctuations

R. Hauser, A. Videnovic, P. Soares-da-Silva, G. Liang, K. Olson, E. Jen, JF. Rocha, O. Klepitskaya (Miami, USA)

Effects of safinamide adjunct therapy on non-motor symptoms in patients with Parkinson’s disease: a post-hoc analysis of the Japanese Phase 2/3 study

N. Hattori, Y. Tsuboi, Y. Kogo, M. Koebisu, T. Ishida, I. Suzuki, M. Nomoto (Tokyo, Japan)

Efficacy of a 6-week brisk walking program in improving non-motor symptoms in people with Parkinson disease – a randomized controlled trial

M. Mak, ISK. Wong-Yu, LJ. Ren (Hong Kong Sar, China)

Efficacy of opicapone according to different levodopa daily intakes in Parkinson’s disease patients with motor fluctuations

G. Ebersbach, W. Poewe, J. Ferreira, D. Magalhaes, J. Rocha, P. Soares-da-Silva (Beelitz-Heilstätten, Germany)

Efficacy of opicapone according to levodopa’s duration of use in Parkinson’s disease patients with motor fluctuations

A. Antonini, G. Ebersbach, O. Rascol, D. Magalhaes, J. Rocha, P. Soares-da-Silva (Padova, Italy)

Evaluating Engagement of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody to Physiological and Pathological Forms of Alpha-Synuclein for Phase 2 Dose Selection: A PBPK Modeling and Simulation Approach

H. Kalluri, S. Bhatnagar, L. Rueter, C. Zadikoff, O. Graff, P. Noertersheuser, H. Xiong (North Chicago, USA)

Evaluation of Motor Function Using Motor Testing App and Deep Learning for the Treatment of Lewy Body Dementia

X. Dang, Y. Guan, K. Deng, J. Wang, H. Zhang, C. Battioui, M. Pugh, B. Winger, J. Yang, K. Biglan (Cambridge, USA)

Feasibility of dance therapy through synchrony videoconference in Parkinson’s disease and elderly people.

C. Pinto, C. Figueiredo, V. Mabilia, I. Cortez, F. Pereira, T. Rosa, I. Bevilacqua, E. Jeffrey, A. Pagnussat (Porto Alegre, Brazil)

Feasibility of Instituting Graduated High intensity Training (FIGHT-PD); Protocol for a non-contact boxing exercise study

D. Blacker, R. Fazio, C. Tucak, M. Turner, S. Rajandran, T. Cruickshank (Nedlands, Australia)

FIRST-IN-MAN CLINICAL TRIAL OF INTRAPUTAMENAL CDNF IN PARKINSON’S DISEASE FINDS A CONSORTED BIOMARKER RESPONSE IN A SUBGROUP OF SUBJECTS

H. Huttunen, S. Booms, M. Sjögren, A. Cryar, J. Harris, E. Sirka, M. Dove, N. Majbour, H. Abdesselem, O. El-Agnaf, J. Koskinen, R. Holmnäs, V. Kerstens, J. Johansson, J. Rinne, A. Varrone, M. Woolley, B. Murphy, P. Fielder, J. Baker, P. Skinner, M. Andreasson, G. Paul-Visse, R. Kivisaari, H. Bjartmarz, G. Lind, P. Almqvist, F. Scheperjans, H. Widner, P. Svenningsson (Espoo, Finland)

Home Health Management of Parkinson’s Disease Deep Brain Stimulation: A Randomized Clinical Trial

G. Duffley, A. Wright, C. Hess, A. Ramirez-Zamora, P. Zeilman, S. Chiu, A. Szabo, B. Lutz, K. Foote, M. Okun, C. Butson (Salt Lake City, USA)

Impact of 3-month earlier versus postponed initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson’s disease and motor fluctuations

C. Carroll, A. Lees, J. Ferreira, M. Fonseca, D. Magalhaes, J. Rocha, P. Soares-da-Silva (Plymouth, United Kingdom)

Impact of specialized light therapy in Parkinson’s disease on MDS-UPDRS parts 1-3 subscales

B. Wyman, S. Hendrix, S. Hennessey, S. Dickson, J. Groves, W. Croft, D. Adams (Draper, USA)

IMPACT OF STANDARD-OF-CARE MEDICATIONS ON TIME-OFF READOUTS IN CLINICAL TRIALS. A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH

R. Rose, E. Mitchell, H. Geerts (Sheffield, United Kingdom)

Impulse Control Disorders Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial

T. Stiep, A. Ramirez-Zamora, A. Tröster, R. Jain, L. Chen, M. Okun (Gainesville, USA)

Indirect Comparison of Apomorphine Sublingual Film Versus Levodopa Inhalation Powder for “OFF” Episodes in Parkinson’s Disease

A. Thach, M. Zichlin, N. Kirson, K. Yang, K. Gaburo, E. Pappert, D. Mehta, G. Williams (Marlborough, USA)

Informing the design of disease modifying trials for Parkinson’s disease – A Delphi study

M. Zeissler, R. Windle, K. Raphael, G. Rafaloff, K. Mcfarthing, H. Matthews, C. Carroll (Plymouth, United Kingdom)

Long-Term Evaluation of Deep Brain Stimulation for Treatment of Parkinson’s Disease Using a Multiple-Source, Constant-Current Rechargeable System: 4-year Follow-Up of a Prospective, Double-Blind RCT

J. Vitek, R. Jain, L. Chen, A. Tröster, L. Schrock, P. House, M. Giroux, A. Hebb, S. Farris, D. Whiting, T. Lechleiter, J. Ostrem, M. San Luciano, N. Galifianakis, L. Verhagen Metman, S. Sani, J. Karl, M. Siddiqui, S. Tatter, I. Ul Haq, A. Machado, M. Gostkowski, M. Tagliati, A. Mamelak, M. Okun, K. Foote, G. Moguel-Cobos, F. Ponce, R. Pahwa, J. Nazarro, C. Buetefisch, R. Gross, C. Luca, J. Jagid, G. Revuelta, I. Takacs, M. Pourfar, A. Mogilner, A. Duker, G. Mandybur, J. Rosenow, S. Cooper, M. Park, S. Khandhar, M. Sedrak, F. Phibbs, J. Pilitsis, R. Uitti, P. Starr (Minneapolis, USA)

Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease

S. Factor, W. Ondo, S. Isaacson, I. Zhang, E. Pappert, B. Navia (Atlanta, USA)

Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Europe vs North America

R. Pahwa, S. Fox, J. Hui, C. Singer, J. Schwarz, M F. de Pandis, J. Raw, I. Zhang, E. Pappert, B. Navia (Kansas City, USA)

LRRK2 Inhibition by BIIB122 / DNL151: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Ph 1 Healthy Volunteer and Ph 1B Parkinson’s Disease Trials

D. Jennings, J. Wetering Derooij, M. Vissers, J. Heuberger, G. Groeneveld, R. Macuica, A. Kay, M. Borin, B. Wong, V. Daryani, S. Huntwork-Rodriguez, P. Chin, C. Ho, M. Troyer (South San Francisco, USA)

Measuring progression of Parkinson’s disease cardinal signs in the Phase 2 SPARK study

KP. Kilambi, T. Dam, J. Edgerton, T. Fox, S. Khan, J. Xiao, M. Yang, P. Bergethon (Cambridge, USA)

Modeling of the Placebo Response in Parkinson’s Disease

S. Branders, O. Rascol, G. Garraux, B. Berman, G. Stebbins, C. Goetz, C. Billocq, A. Pereira (Mont-Saint-Guibert, Belgium)

Non-motor symptoms in Parkinson’s disease

M. Elfekih, I. Bedoui, B. Douma, M. Mansour, H. Derbali, A. Riahi, M. Meselmani, J. Zaouali, R. Mrissa (Nabeul, Tunisia)

OPTI-ON: A Longitudinal Real-World Study of Opicapone in Patients with Parkinson’s Disease and Motor Fluctuations

P. Lewitt, O. Klepitskaya, L. Bahroo, G. Liang, S. Rattana, J. Trotter, M. Serbin (West Bloomfield, USA)

Overcoming clinical research challenges during a pandemic: selection and implementation of digital phenotyping solutions in a natural history study of G2019S LRRK2 Parkinson’s disease.

N. France, C. Tomkins-Lane, M. Maurer, C. Barlow, E. Davies, C. Matthews, A. Palozoglu, L. Farid (South San Francisco, USA)

PARK-BAND training program for Parkinson’s disease in clinical settings: A feasibility study.

D. Lima, J. Bonfadini, S. Almeida, E. Sobreira, P. Damasceno, M. Alencar, A. Viana-Júnior, J. Luna, P. Rodrigues, I. Pereira, A. Gadelha, P. Oliveira, E. Chaves, L. Oliveira, V. Gomes, R. Monteiro, T. Costa, L. Lima, M. Sobreira-Neto, P. Braga-Neto (Fortaleza, Brazil)

Parkinson Progression Marker Initiative – New Science/New Cohorts

K. Marek, A. Siderowf, T. Simuni, L. Chahine, K. Kieburtz, B. Mollenhauer, D. Galasko, K. Merchant, E. Brown, C. Coffey, R. Dobkin, T. Foroud, K. Poston, E. Flagg, S. Chowdhury, C. Tanner (New Haven, USA)

Pharmacokinetic–pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy

T. Birnberg, L. Adar, W. Poewe, M. Bjornsson, M. Karlsson (Rehovot, Israel)

Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort at 6 Months

G. Corcoran, A. Karunakara, B. Vaughn, E. Brand-Schieber, T. Foltynie, R. Barker, S. Palfi (New York, USA)

PHYSICAL ACTIVITY AT HOME IS ABLE TO REDUCE THE WORSENING IN QUALITY OF LIFE IN PARKINSON’S DISEASE DURING COVID-19 PANDEMIC

I. Nascimento, C. Batista, D. Coelho, L. Almeida, A. Guimarães, A. Lindquist, V. Israel, H. Kanegusuku, R. Guimarães, N. Bosaipo, R. Barbosa, C. Correa, M. Finatto, F. Mendes, R. Azamor, M. Piemonte (São Paulo, Brazil)

Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1

K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, D. Rukina, J. Anzures Cabrera, L. Essioux, M. Abt, B. van Lier, A. Thomann, H. Svoboda, W. Zago, R. Postuma, G. Pagano, M. Lindemann (Basel, Switzerland)

Randomised Controlled Trial Comparing Efficacy of Zonisamide 25 mg given in addition to standard treatment with standard treatment alone in Tremor dominant Parkinson’s Disease- A Pilot study.

K. Pillai, V. Goyal, A. Srivastava, R. Rajan, P. Srivastava, M. Singh, V. V.Y, D. Radhakrishnan, A. Elavarasi, P. Bhat (New Delhi, India)

Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody in Healthy Subjects

H. Kalluri, C. Zadikoff, L. Rueter, O. Graff, H. Xiong (North Chicago, USA)

Re-thinking enrollment of Deep Brain Stimulation patients in Parkinson’s Disease Clinical Trials

J. Jimenez-Shahed, J. Rosenow, S. Miocinovic, L. Luo, C. Aquino, D. Corcos, P. Agarwal (New York, USA)

Relationship of satisfaction and adherence in remote digital monitoring: Results from a clinical drug trial in early Parkinson’s disease

B. Fehlmann, A. Thomann, W. Popp, F. Lipsmeier, E. Volkova-Volkmar, J. Friess, H. Svoboda, G. Pagano, T. Kilchemann, A. Bamdadian, W. Zago, R. Postuma, M. Lindemann, K. Taylor (Basel, Switzerland)

Remote Art Therapy is feasible and may benefit individuals with Parkinson’s disease

J. Rieders, K. Astudillo, D. Mania, R. Kilachand, M. Berberian, I. Acosta, A. Cucca, A. Feigin (New York, USA)

RESPONDING TO COVID-19: THE “ALMEIDA-SANG EQUATION” TO PREDICT TOTAL DISEASE SEVERITY IN PARKINSON’S

K. Sangarapillai, B. Norman, Q. Almeida (Waterloo, Canada)

Reversible MIBG Abnormalities in Subjects at Risk for Synucleinopathy: 12 months data

H. Maghzi, E. Hogg, E. Tan, G. Obiliasi, G. Pagano, M. Tagliati (Los Angeles, USA)

Secondary endpoints of a randomized, placebo-Controlled Pilot Study to evaluate the safety of lyophilized PRIM-DJ2727 in Parkinson’s disease

J. Suescun, M. Schiess, Z. Jiang, V. Thyne, T. Iqbal, N. Utay, M. Newmark, A. Dupont, A. Alexander, H. Dupont (Houston, USA)

Should Amantadine DR/ER Be Considered Prior to Device-Aided Therapies for Parkinson’s Disease?

R. Hauser, S. Goud, A. Formella (Tampa, USA)

Single-Trajectory Multiple-Target Deep Brain Stimulation to treat Mobility and Cognition in Parkinson’s Disease: a Double-Blind, Randomized, Cross-Over Pilot Study

S. Sasikumar, M. Cohn, I. Harmsen, A. Loh, S. Kalia, A. Lozano, A. Fasano (Toronto, Canada)

Study Design to Assess the Effect of Opicapone on Levodopa PK at Different Levodopa-Optimized Treatment Regimens in Parkinson’s Disease Patients

J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

Subcutaneous Levodopa Infusion for Parkinson’s disease Patients with Motor Fluctuations: Open-Label Efficacy Outcomes from the BeyoND study

W. Poewe, F. Stocchi, L. Adar, R. Case, T. Yardeni, A. Espay (Innsbruck, Austria)

Telephone Visit Efficacy for Parkinson’s Disease During the COVID-19 Pandemic

F. Abu Ahmad, R. Postuma (Montreal, Canada)

The ADOPTION (eArly levoDopa with Opicapone in Parkinson’s paTients wIth motOr fluctuatioNs) study in Parkinson’s disease: design and rationale of a randomized prospective, open-label exploratory trial

J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

The effect of Nordic Walking on respiratory function, pain and gait in Parkinson’s disease

J. Stożek, W. Falewska, S. Podsiadło (Krakow, Poland)

The effect of Tuina in Traditional Chinese Medicine in treatment of Parkinson’s disease (Non-motor symptoms): a pilot clinical study

FY. Chung, HY. Lai, CS. Yuen, HW. Lam, KY. Lai, SM. Chan, M. Li, KK. Chua (Hong Kong, Hong Kong)

The Effects of Telepractice- Based LSVT-BIG Training in Patients with Parkinson’s Disease in Covid-19 pandemic: Preliminary Results

G. Kaya Aytutuldu, B. Ersoz Huseyinsinoglu, N. Karagoz Sakalli, A. Sen (İstanbul, Turkey)

The EPSILON (Early ParkinSon wIth L-dopa/DDCi and OpicapoNe) study in early Parkinson’s disease: design and rationale of a phase III, double-blind, randomized, placebo-controlled study

J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

The Hauser Diary knowledge test as a tool to improve Rater Training Programs in Parkinson’s disease clinical trials

C. Mañeru, S. Meyer (Barcelona, Spain)

The Impact of Visual Cueing on Gait Velocity in those with Parkinson’s Disease with Freezing of Gait

M. Scavarda, K. Nagel, D. Peterson, K. Plesher, S. Moskowitz, C. Ivy, L. Denney (Phoenix, USA)

The OASIS (OpicApone in Sleep dISorder) study in Parkinson’s disease: design and rationale of an open-label, single-arm, pilot trial

R. Costa, C. Trenkwalder, J. Ferreira, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

The OCEAN (OpiCapone Effect on motor fluctuations and associated pAiN) study in Parkinson’s disease: design and rationale of a randomized double-blind placebo-controlled trial

K. Chaudhuri, P. Odin, J. Ferreira, A. Antonini, O. Rascol, M. Kurtis, A. Storch, K. Bannister, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

The Role of the PD Diary Trainer/Reviewer in Parkinson’s Disease Clinical Trials

C. Mañeru, S. Meyer (Barcelona, Spain)

Therapy to Reduce dementia risk In Parkinson’s disease (TRIP): Proof-of-concept trial

D. Pourzinal, A. Bakker, G. Byrne, K. Mcmahon, J. O'Sullivan, R. Adam, A. Lehn, D. Copland, J. Yang, G. Pontone, T. Au, R. Littleford, M. Chatfield, Z. Mari, N. Dissanayaka (Herston, Australia)

Towards an automated rating of the MDS-UPDRS motor scores.

S. Marchal, G. Garraux, S. Branders, G. Bernard, C. Billocq, A. Pereira (Mont-Saint-Guibert, Belgium)

Trunk postural control in seated position on a prototype of unstable chair and the interference of cognitive and motor tasks in individuals with Parkinson disease

H. Araújo, A. Miri, R. Volpe, M. Oliveira, R. Silva Jr, S. Smaili (Londrina, Brazil)

Unilateral Subthalamic Versus Unilateral Pallidal Stimulation in Parkinson’s Disease: A Randomized Double-Blind Crossover Study

ZT. Zeng, LB. Wang, WK. Shi, ZY. Lin, BM. Sun, CC. Zhang, DY. Li (Shanghai, China)

Visuo-cognitive training in Parkinson’s disease: Protocol for a randomised cross-over trial.

J. Das, R. Morris, G. Barry, R. Walker, S. Stuart (Newcastle Upon Tyne, United Kingdom)

WATCH-PD: Wearable Assessments in the Clinic and Home in Parkinson’s Disease: Baseline Analyses

J. Adams, E. Dorsey, T. Ruiz Herrero, P. Auinger, R. Alexander, R. Rubens, B. Tracey, N. Zach, P. O'Donnell, A. Best, J. Severson, M. Kostrzebski, E. Stevenson, P. Wilmot, Y. Pohlson, J. Cosman, K. Fisher, J. Edgerton, T. Kangarloo (Rochester, USA)